Immunomedics, Inc. Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers

Published: Apr 03, 2012

CHICAGO, April 2, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the development of two bispecific, hexavalent antibodies for treating breast, pancreatic and other solid cancers.

Back to news